Objective To explore the relationship of plasma NT-proBNP level and severity of chronic congestive heart failure (CHF) and investigate the curative effect and security of meglumine adenosine cyclophosphate (MAC) combined with perindopril on patients with CHF.Methods From June 2011 to June 2013,126 inpatients with chronic congestive heart failure were randomly divided into A group (42 cases,routine therapy),B group (41 cases,routine therapy and perindopril) and C group (43 cases,routine therapy and perindopril plus MAC),all cases treated for 14 days.The left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) by echocardiography and plasma NT-proBNP levels were evaluated before and after 14 days therapy.Results The plasma NT-proBNP levels in NYHA Ⅱ ~ Ⅳ classes were significantly difference compared each other between any two classes (P <0.05) and the levels was positively correlated with NYHA cardiac function class and LVEDD (r =0.617,P < 0.01 ; r =0.412,P < 0.01),negatively correlated with LVEF (r =-0.372,P < 0.01).After 14 days therapy,compared with A group,the LVEF and LVEDD significantly improved (P < 0.05) and NT-proBNP level significantly decreased (P < 0.05) in B,C groups; Compared with B group,C group had lower NT-proBNP level (P < 0.05) although no further improvement in cardiac function.Conclusions The plasma NT-proBNP level is correlated closely with the severity of CHF and it is a good examination of diagnose,therapy and evaluating prognosis of CHF.Perindopril may significantly decline plasma NT-proBNP level and improve cardiac function of CHF patients,combined with MAC may further decline plasma NT-proBNP level although not further improved LVEF.Giving MAC and perindopril to patients with CHF was secure and patients tolerated it well. Key words: Melamine adenosine cyclophosphate; Perindopril; N-terminal pro-brain natriuretic peptide; Congestive heart failure